Summary

The global Viral and Non-viral Vector market was valued at US$ 551.85 million in 2023 and is anticipated to reach US$ 3505 million by 2030, witnessing a CAGR of 31.84% during the forecast period 2024-2030.
North American market for Viral and Non-viral Vector is estimated to increase from $ 232 million in 2023 to reach $ 1423million by 2030, at a CAGR of 31% during the forecast period of 2024 through 2030.
Asia-Pacific market for Viral and Non-viral Vector is estimated to increase from $ 141 million in 2023 to reach $ 983 million by 2030, at a CAGR of 33.67% during the forecast period of 2024 through 2030.
The major global companies of Viral and Non-viral Vector include Lonza, Thermo Fisher Scientific, VectorBuilder, GenScript Biotech, Gene Chem, Revvity, etc. In 2023, the world's top five vendors accounted for approximately 62.03 % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Viral and Non-viral Vector, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral and Non-viral Vector.

The Viral and Non-viral Vector market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral and Non-viral Vector market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Viral and Non-viral Vector companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation
By Company
Thermo Fisher Scientific
Lonza
Azenta Life Sciences
Revvity
VectorBuilder
Takara Bio
GenScript Biotech
Gene Chem
Geno Meditech
PackGene Biotech
VIROVEK
OriGen
Vector BioLabs

Segment by Type
AAV
Lentiviruses
Retroviruses
Adenoviruses
DNA Plasmids
Others

Segment by Application
Pharmaceutical and Biopharmaceutical Companies
Academics and Research Institutes
Others

By Region
North America
United States
Canada
Mexico

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia

Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe

South America
Brazil
Rest of South America

Middle East & Africa
Middle East
Africa

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral and Non-viral Vector company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

ページTOPに戻る

Table of Contents

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Viral and Non-viral Vector Market Size Growth Rate by Type: 2019 VS 2023 VS 2030 1
1.2.2 AAV 4
1.2.3 Lentiviruses 4
1.2.4 Retroviruses 5
1.2.5 Adenoviruses 5
1.2.6 DNA Plasmids 6
1.3 Market by Application 6
1.3.1 Global Viral and Non-viral Vector Market Growth by Application: 2019 VS 2023 VS 2030 7
1.3.2 Pharmaceutical and Biopharmaceutical Companies 9
1.3.3 Academics and Research Institutes 10
1.4 Assumptions and Limitations 11
1.5 Study Objectives 12
1.6 Years Considered 13
2 Global Growth Trends 14
2.1 Global Viral and Non-viral Vector Market Perspective (2019-2030) 14
2.2 Global Viral and Non-viral Vector Growth Trends by Region 15
2.2.1 Global Viral and Non-viral Vector Market Size by Region: 2019 VS 2023 VS 2030 16
2.2.2 Viral and Non-viral Vector Historic Market Size by Region (2019-2024) 18
2.2.3 Viral and Non-viral Vector Forecasted Market Size by Region (2025-2030) 19
2.3 Viral and Non-viral Vector Market Dynamics 19
2.3.1 Viral and Non-viral Vector Industry Trends 19
2.3.2 Viral and Non-viral Vector Market Drivers 21
2.3.3 Viral and Non-viral Vector Market Challenges 22
2.3.4 Viral and Non-viral Vector Market Restraints 23
3 Competition Landscape by Key Players 24
3.1 Global Top Viral and Non-viral Vector Players by Revenue 24
3.1.1 Global Top Viral and Non-viral Vector Players by Revenue (2019-2024) 24
3.1.2 Global Viral and Non-viral Vector Revenue Market Share by Players (2019-2024) 25
3.2 Global Viral and Non-viral Vector Market by Company Type (Tier 1, Tier 2, and Tier 3) 26
3.3 Global Key Players Ranking by Viral and Non-viral Vector Revenue 27
3.4 Global Viral and Non-viral Vector Market Concentration Ratio 28
3.4.1 Global Viral and Non-viral Vector Market Concentration Ratio (CR5 and HHI) 28
3.4.2 Global Top 10 and Top 5 Companies by Viral and Non-viral Vector Revenue in 2023 29
3.5 Global Key Players of Viral and Non-viral Vector Head office and Area Served 30
3.6 Global Key Players of Viral and Non-viral Vector, Product 31
3.7 Global Key Players of Viral and Non-viral Vector, Founded Date 31
3.8 Mergers & Acquisitions, Expansion Plans 32
4 Viral and Non-viral Vector Breakdown Data by Type 34
4.1 Global Viral and Non-viral Vector Historic Market Size by Type (2019-2024) 34
4.2 Global Viral and Non-viral Vector Forecasted Market Size by Type (2025-2030) 35
5 Viral and Non-viral Vector Breakdown Data by Application 36
5.1 Global Viral and Non-viral Vector Historic Market Size by Application (2019-2024) 36
5.2 Global Viral and Non-viral Vector Forecasted Market Size by Application (2025-2030) 37
6 North America 38
6.1 North America Viral and Non-viral Vector Market Size (2019-2030) 38
6.2 North America Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030 38
6.3 North America Viral and Non-viral Vector Market Size by Country (2019-2024) 39
6.4 North America Viral and Non-viral Vector Market Size by Country (2025-2030) 39
6.5 United States 40
6.6 Canada 41
6.7 Mexico 42
7 Europe 43
7.1 Europe Viral and Non-viral Vector Market Size (2019-2030) 43
7.2 Europe Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030 43
7.3 Europe Viral and Non-viral Vector Market Size by Country (2019-2024) 44
7.4 Europe Viral and Non-viral Vector Market Size by Country (2025-2030) 44
7.5 Germany 45
7.6 France 46
7.7 U.K. 46
7.8 Italy 47
7.9 Russia 47
7.10 Spain 48
8 Asia-Pacific 49
8.1 Asia-Pacific Viral and Non-viral Vector Market Size (2019-2030) 49
8.2 Asia-Pacific Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030 49
8.3 Asia-Pacific Viral and Non-viral Vector Market Size by Region (2019-2024) 50
8.4 Asia-Pacific Viral and Non-viral Vector Market Size by Region (2025-2030) 50
8.5 China 52
8.6 Japan 52
8.7 South Korea 53
8.8 Southeast Asia 53
8.9 India 54
8.10 Australia 54
9 South America 55
9.1 South America Viral and Non-viral Vector Market Size (2019-2030) 55
9.2 South America Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030 55
9.3 South America Viral and Non-viral Vector Market Size by Country (2019-2024) 56
9.4 South America Viral and Non-viral Vector Market Size by Country (2025-2030) 56
9.5 Brazil 57
10 Middle East & Africa 58
10.1 Middle East & Africa Viral and Non-viral Vector Market Size (2019-2030) 58
10.2 Middle East & Africa Viral and Non-viral Vector Market Growth Rate by Country: 2019 VS 2023 VS 2030 58
10.3 Middle East & Africa Viral and Non-viral Vector Market Size by Country (2019-2024) 59
10.4 Middle East & Africa Viral and Non-viral Vector Market Size by Country (2025-2030) 59
10.5 Middle East 60
10.6 Africa 61
11 Key Players Profiles 62
11.1 Thermo Fisher Scientific 62
11.1.1 Thermo Fisher Scientific Company Details 62
11.1.2 Thermo Fisher Scientific Business Overview 62
11.1.3 Thermo Fisher Scientific Viral and Non-viral Vector Introduction 63
11.1.4 Thermo Fisher Scientific Revenue in Viral and Non-viral Vector Business (2019-2024) 64
11.1.5 Thermo Fisher Scientific Recent Development 64
11.2 Lonza 65
11.2.1 Lonza Company Details 65
11.2.2 Lonza Business Overview 66
11.2.3 Lonza Viral and Non-viral Vector Introduction 66
11.2.4 Lonza Revenue in Viral and Non-viral Vector Business (2019-2024) 68
11.2.5 Lonza Recent Development 68
11.3 Azenta Life Sciences 69
11.3.1 Azenta Life Sciences Company Details 69
11.3.2 Azenta Life Sciences Business Overview 70
11.3.3 Azenta Life Sciences Viral and Non-viral Vector Introduction 70
11.3.4 Azenta Life Sciences Revenue in Viral and Non-viral Vector Business (2019-2024) 71
11.3.5 Azenta Life Sciences Recent Development 72
11.4 Revvity 73
11.4.1 Revvity Company Details 73
11.4.2 Revvity Business Overview 73
11.4.3 Revvity Viral and Non-viral Vector Introduction 74
11.4.4 Revvity Revenue in Viral and Non-viral Vector Business (2019-2024) 76
11.5 VectorBuilder 76
11.5.1 VectorBuilder Company Details 76
11.5.2 VectorBuilder Business Overview 77
11.5.3 VectorBuilder Viral and Non-viral Vector Introduction 77
11.5.4 VectorBuilder Revenue in Viral and Non-viral Vector Business (2019-2024) 79
11.5.5 VectorBuilder Recent Development 80
11.6 Takara Bio 81
11.6.1 Takara Bio Company Details 81
11.6.2 Takara Bio Business Overview 81
11.6.3 Takara Bio Viral and Non-viral Vector Introduction 82
11.6.4 Takara Bio Revenue in Viral and Non-viral Vector Business (2019-2024) 86
11.6.5 Takara Bio Recent Development 86
11.7 GenScript Biotech 88
11.7.1 GenScript Biotech Company Details 88
11.7.2 GenScript Biotech Business Overview 89
11.7.3 GenScript Biotech Viral and Non-viral Vector Introduction 89
11.7.4 GenScript Biotech Revenue in Viral and Non-viral Vector Business (2019-2024) 90
11.7.5 GenScript Biotech Recent Development 91
11.8 Gene Chem 92
11.8.1 Gene Chem Company Details 92
11.8.2 Gene Chem Business Overview 92
11.8.3 Gene Chem Viral and Non-viral Vector Introduction 93
11.8.4 Gene Chem Revenue in Viral and Non-viral Vector Business (2019-2024) 94
11.9 Geno Meditech 94
11.9.1 Geno Meditech Company Details 95
11.9.2 Geno Meditech Business Overview 95
11.9.3 Geno Meditech Viral and Non-viral Vector Introduction 96
11.9.4 Geno Meditech Revenue in Viral and Non-viral Vector Business (2019-2024) 97
11.10 PackGene Biotech 98
11.10.1 PackGene Biotech Company Details 98
11.10.2 PackGene Biotech Business Overview 99
11.10.3 PackGene Biotech Viral and Non-viral Vector Introduction 99
11.10.4 PackGene Biotech Revenue in Viral and Non-viral Vector Business (2019-2024) 100
11.11 VIROVEK 101
11.11.1 VIROVEK Company Details 101
11.11.2 VIROVEK Business Overview 102
11.11.3 VIROVEK Viral and Non-viral Vector Introduction 102
11.11.4 VIROVEK Revenue in Viral and Non-viral Vector Business (2019-2024) 103
11.11.5 VIROVEK Recent Development 104
11.12 OriGen 104
11.12.1 OriGen Company Details 104
11.12.2 OriGen Business Overview 105
11.12.3 OriGen Viral and Non-viral Vector Introduction 105
11.12.4 OriGen Revenue in Viral and Non-viral Vector Business (2019-2024) 106
11.13 Vector BioLabs 107
11.13.1 Vector BioLabs Company Details 107
11.13.2 Vector BioLabs Business Overview 108
11.13.3 Vector BioLabs Viral and Non-viral Vector Introduction 108
11.13.4 Vector BioLabs Revenue in Viral and Non-viral Vector Business (2019-2024) 109
11.13.5 Vector BioLabs Recent Development 110
12 Analyst's Viewpoints/Conclusions 111
13 Appendix 113
13.1 Research Methodology 113
13.1.1 Methodology/Research Approach 113
13.1.2 Data Source 116
13.2 Author Details 119
13.3 Disclaimer 119